BeOne Medicines Ltd
192 hedge funds and large institutions have $6.66B invested in BeOne Medicines Ltd in 2018 Q4 according to their latest regulatory filings, with 82 funds opening new positions, 65 increasing their positions, 30 reducing their positions, and 32 closing their positions.
156% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 32
140% more call options, than puts
Call options by funds: $50.8M | Put options by funds: $21.1M
117% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 30
56% more funds holding in top 10
Funds holding in top 10: 9 → 14 (+5)
33% more funds holding
Funds holding: 144 → 192 (+48)
0.23% more ownership
Funds ownership: 5.95% → 6.18% (+0.23%)
15% less capital invested
Capital invested by funds: $7.84B → $6.66B (-$1.18B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$186M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$136M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$74.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$68.8M |
| 5 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
+$44.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$589M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
-$348M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$315M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$44.4M |
| 5 |
Renaissance Technologies
New York
|
-$24.5M |
ONC Hedge Fund Activity: Q4 2018 in Review
192 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q4 2018, worth a combined $6.66B — down 15% from $7.84B a quarter earlier.
Buyers outnumbered sellers: 82 funds opened new ONC positions and 32 closed out — a net gain of 50 holders — while 65 added to existing stakes and 30 trimmed.
The largest buyer was BlackRock, adding an estimated $186M. The largest seller was Hillhouse Investment Management, cutting an estimated $589M.
- 192 institutional investors held BeOne Medicines Ltd (ONC) as of Q4 2018, up from 144 in Q3 2018.
- Funds reported $6.66B of BeOne Medicines Ltd stock for Q4 2018, down 15% quarter-over-quarter.
- 82 funds opened new BeOne Medicines Ltd positions in Q4 2018 and 32 closed out, a net change of +50 holders.
- The largest BeOne Medicines Ltd buyer in Q4 2018 was BlackRock, an estimated $186M added.
- The largest BeOne Medicines Ltd seller in Q4 2018 was Hillhouse Investment Management, an estimated $589M sold.
Based on aggregated 13F filings for Q4 2018.